Literature DB >> 29322620

Rice Protein Matrix Enhances Circulating Levels of Xanthohumol Following Acute Oral Intake of Spent Hops in Humans.

Annalouise O'Connor1, Veera Konda1, Ralph L Reed2,3, J Mark Christensen2, Jan F Stevens2,3, Nikhat Contractor1.   

Abstract

SCOPE: Xanthohumol (XN), a prenylated flavonoid found in hops, exhibits anti-inflammatory and antioxidant properties. However, poor bioavailability may limit therapeutic applications. As food components are known to modulate polyphenol absorption, the objective is to determine whether a protein matrix could enhance the bioavailability of XN post oral consumption in humans. METHODS AND
RESULTS: This is a randomized, double-blind, crossover study in healthy participants (n = 6) evaluating XN and its major metabolites (isoxanthohumol [IX], 6- and 8-prenylnaringenin [6-PN, 8-PN]) for 6 h following consumption of 12.4 mg of XN delivered via a spent hops-rice protein matrix preparation or a control spent hops preparation. Plasma XN and metabolites are measured by LC-MS/MS. Cmax , Tmax , and area-under-the-curve (AUC) values were determined. Circulating XN and metabolite response to each treatment was not bioequivalent. Plasma concentrations of XN and XN + metabolites (AUC) are greater with consumption of the spent hops-rice protein matrix preparation.
CONCLUSION: Compared to a standard spent hops powder, a protein-rich spent hops matrix demonstrates enhanced plasma levels of XN and metabolites following acute oral intake.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  bioavailability; human subjects; xanthohumol

Mesh:

Substances:

Year:  2018        PMID: 29322620     DOI: 10.1002/mnfr.201700692

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  3 in total

1.  Xanthohumol Microbiome and Signature in Healthy Adults (the XMaS Trial): Safety and Tolerability Results of a Phase I Triple-Masked, Placebo-Controlled Clinical Trial.

Authors:  Blake O Langley; Jennifer Joan Ryan; Douglas Hanes; John Phipps; Emily Stack; Thomas O Metz; J Frederik Stevens; Ryan Bradley
Journal:  Mol Nutr Food Res       Date:  2021-03-11       Impact factor: 5.914

2.  8-Prenylnaringenin tissue distribution and pharmacokinetics in mice and its binding to human serum albumin and cellular uptake in human embryonic kidney cells.

Authors:  Yoshiaki Tanaka; Hitomi Okuyama; Miyu Nishikawa; Shin-Ichi Ikushiro; Mayumi Ikeda; Yu Ishima; Yuichi Ukawa; Kenichi Oe; Junji Terao; Rie Mukai
Journal:  Food Sci Nutr       Date:  2022-01-22       Impact factor: 2.863

3.  Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial.

Authors:  Ryan Bradley; Blake O Langley; Jennifer J Ryan; John Phipps; Douglas A Hanes; Emily Stack; Janet K Jansson; Thomas O Metz; Jan Frederik Stevens
Journal:  Trials       Date:  2020-10-07       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.